Taken together, these results suggest that HOXB3 hypo-methylation may be the most valuable prognostic biomarker among the HOXB genes in AML, especially in non-M3 AML, and was selected for further analysis. This evidence concerns the gene HOXB3 and acute myeloid leukemia.